IceCure Medical (ICCM) CEO details share, RSU and option stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
IceCure Medical Ltd. filed an initial ownership report for Chief Executive Officer Eyal Shamir, detailing his existing equity position. As of March 18, 2026, he directly holds 791,381 ordinary shares, plus a range of vested and unvested equity awards.
Footnotes show additional exposure through restricted share units granted on May 15, 2025; November 5, 2025; and March 16, 2026, with portions vesting in 25% cliffs and 6.25% quarterly installments thereafter. Shamir also holds multiple fully or partially vested share options over ordinary shares with exercise prices converted from Israeli shekels into U.S. dollars, including options over 117,551 shares at an exercise price of $0.82 per share expiring January 23, 2027, and several later grants expiring between 2028 and 2033. The filing records these as holdings only, with no reported recent purchases, sales, or option exercises.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Shamir Eyal
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Share option (right to buy) — 117,551 shares (Direct);
Ordinary shares — 791,381 shares (Direct)
Footnotes (1)
- Represents (i) 77,894 ordinary shares, (ii) 525,949 restricted share units ("RSUs") granted on May 15, 2025, 25% of which vest on July 1, 2025 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, of which 197,230 RSUs have vested and 328,719 remain unvested as of March 18, 2026, (iii) 121,893 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iv) 65,645 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026. A total of 156,734 options were granted on January 23, 2017, and vested in equal quarterly installments of 6.25% beginning September 1, 2016. As of March 18, 2026, 117,551 options are fully vested and 39,183 have been exercised into ordinary shares. The options were granted with an exercise price of NIS 2.54 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $0.82 per share. The options were granted on May 2, 2018, and vested in equal quarterly installments of 6.25% beginning May 2, 2018. As of March 18, 2026, all 7,091 options are fully vested. The options were granted with an exercise price of NIS 2.992 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $0.97 per share. The options were on August 14, 2018, and vested in equal quarterly installments of 6.25% beginning August 14, 2018. As of March 18, 2026, all 125,000 options are fully vested. The options were granted with an exercise price of NIS 6.472 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.09 per share. The options were granted on March 28, 2019, and vested in equal quarterly installments of 6.25% beginning March 28, 2019. As of March 18, 2026, all 9,726 options are fully vested. The options were granted with an exercise price of NIS 7.04 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.27 per share. The options were granted on May 21, 2019, and vested in equal quarterly installments of 6.25% beginning May 21, 2019. As of March 18, 2026, all 26,000 options are fully vested. The options were granted with an exercise price of NIS 5.536 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.79 per share. The options were granted on August 30, 2020, and vested in equal quarterly installments of 6.25% beginning August 30, 2020. As of March 18, 2026, all 27,332 options are fully vested. The options were granted with an exercise price of NIS 4.84 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share. The options were granted on October 28, 2020, 25% of which vested on October 28, 2021, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 32,500 options are fully vested. The options were granted with an exercise price of NIS 5.2128 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.68 per share. The options were granted on April 28, 2021, 25% of which vested on April 28, 2022, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 4,319 options are fully vested. The options were granted with an exercise price of NIS 17.92 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $5.78 per share. The options were granted on January 12, 2022, 25% of which vested on January 12, 2023, and the remaining 75% vested in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, all 143,324 options are fully vested. The options were granted with an exercise price of NIS 11.29 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $3.64 per share. The options were granted on March 23, 2022, 25% of which vested on March 23, 2023, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 12,862 options are vested. The options were granted with an exercise price of NIS 8.81 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $2.84 per share. The options were granted on February 19, 2023, 25% of which vested on February 19, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 54,240 options are vested. The options were granted with an exercise price of NIS 4.68 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 3.10 to USD $1.00 as of March 11, 2026, resulting in an exercise price of $1.51 per share.
FAQ
What does this Form 3 filing show for IceCure Medical (ICCM) CEO Eyal Shamir?
The Form 3 shows CEO Eyal Shamir’s existing equity stake in IceCure Medical, including 791,381 ordinary shares and multiple option and RSU grants with specified vesting schedules and exercise prices as of March 18, 2026.
Why are option exercise prices in IceCure Medical (ICCM) Form 3 shown in U.S. dollars?
IceCure granted options with exercise prices in Israeli shekels, then converted them into U.S. dollars for this Form 3 using an exchange rate of NIS 3.10 to $1.00 as of March 11, 2026, to present comparable U.S. dollar exercise prices.